Financial Statements and Highlights | Takeda Investor Relations

EN

glasses laying on a book with stock options

Financial Highlights

Loading feed metadata...

Sign up for our investors newsletter

Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

Recent News

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

January 5, 2026

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

December 18, 2025

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

December 6, 2025

Takeda Announces Closing of Strategic Partnership with Innovent Biologics for Next-Generation Investigational Oncology Medicines

December 4, 2025

Explore

Investor Events

Access our IR events calendar and recaps of past events

Our Pipeline

Learn more about our dynamic and diverse pipeline